Schizophrenia is considered to be among the most severe, debilitating and persistent of all psychiatric disorders. Although the adult prevalence is approximately 1%, studies have indicated that sufferers constitute close to 10% of the permanently disabled population.
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studies. 6, [10] [11] [12] [13] [14] [15] Strategies include adjunctive antipsychotic medications, mood stabilisers and novel anticonvulsants, antidepressants such as selective serotonin re-uptake inhibitors and others, glycinergic agents, dopamine agonists, mazindol, omega-3 fatty acids and electroconvulsive therapy (ECT).
The combined use of clozapine and ECT was first proposed in 1990 by Fink and reported on in 1991. 9, 15, 16 A recent literature review on ECT-clozapine bitherapy in patients with treatmentrefractory schizophrenia previously treated with clozapine monotherapy revealed 72% of reported cases to have had a beneficial response on the combination treatment. 17 To date, the largest single study reported on in the literature is an open-label study evaluating ECT-clozapine bitherapy in 11 clozapine nonresponders, with 8 meeting remission criteria after treatment. 18 Safety issues could be regarded as one potential concern when considering the use of ECT-clozapine bitherapy. It is known that clozapine use may lead to an increased risk of seizures or even prolonged seizures due to the threshold-lowering effects of clozapine. 19, 20 Both ECT and clozapine may also cause cardiac arrhythmias, and memory effects have been described. [21] [22] [23] However, a recent review article on somatic augmentation strategies in clozapine-refractoriness by Tranulis et al. found that only seven incidences of significant side-effects in ECTclozapine bitherapy had been described, with no fatalities. 24 They concluded ECT to be a safe and tolerable clozapine augmentation strategy.
In conclusion, although the body of evidence in the literature for the use of ECT-clozapine bitherapy in clozapine-refractory schizophrenia is still far from permitting comprehensive evidencebased conclusions, there seems to be some support with regard to both the efficacy and the safety of the combination. Owing to the rate of clozapine-refractory admissions seen at Stikland Hospital each year, clinicians have had to develop management guidelines to ensure a more structured approach to these clients. A decision was therefore made to use ECT as a first-line add-on strategy based on ECT accessibility in comparison with the limited or nonexistent availability of most of the other strategies described in the literature. Current clinical practice therefore dictates that known clozapine-refractory patients who relapse due to non-compliance are treated with the ECT-clozapine bitherapy when readmitted, if consent for ECT can be obtained. For patients who do not give consent for ECT, treatment with clozapine is restarted and once a maximum tolerable dose or 400 mg is reached and they still have not shown an adequate response, add-on medication is initiated.
This strategy was implemented at the same time as the naturalistic active control study.
Methods

Subjects
Ten known clozapine-refractory patients with a diagnosis of schizophrenia or schizoaffective disorder were recruited from the acute wards of Stikland Psychiatric Hospital, Western Cape. In order to be included patients had to meet the following criteria: 
Procedures
All patients who met the inclusion criteria were screened by the primary investigator after ECT had been discussed with them by their treating clinician. The patients who consented to the study were divided into two groups (depending on whether they gave consent for ECT or not). 
Data collection
Patients were screened 4 -6 days before the first administration of ECT (those who did not consent to ECT were screened 7 days before clozapine was started); if they met inclusion criteria and consent was obtained, the baseline visit took place during that same visit. All data were collected on data sheets which included all demographic data, information on previous admissions and medication history. A PANSS was performed at baseline (day 0), day 21 and day 42. Clinical case notes were retrospectively accessed after discharge and any documented adverse events, the exact length of stay and the medication data (including concomitant medications) were noted. The investigators were not involved in the primary treatment of any of these patients and had no contact with them other than the study visits.
Statistical analysis
The data were entered into Excel sheets and data analysis was performed using the Software Package for Social Sciences (SPSS). Chi-square and Student's t-tests (Fisher's exact) were utilised depending on the tested variables.
Ethical considerations
The study was approved by the Committee for Human Research of Stellenbosch University and their prescribed ethical guidelines were strictly adhered to.
Results
Ten patients were enrolled in the study. Five patients consented to concomitant ECT treatment (EG), whereas the other 5 were started on clozapine only as per the usual treatment protocol (CG). Of these patients 8 were male and 7 reported an educational level of The average PANSS scores in both groups dropped over the 42-day study period for all three of the subscales measured (i.e.
positive, negative, general). No statistically significant differences could be observed between the two groups at any point for any of the subscales or for the total score. Table I Other concomitant medications during admission comprised articles 
Discussion
The management of patients with schizophrenia has proved to be challenging in various aspects, and especially relevant to this study is the problem of clozapine refractoriness. In this pilot study, ECT-clozapine bitherapy was investigated as one strategy to manage such patients in a resource-constrained setting.
No statistically significant advantage of ECT-clozapine bitherapy above clozapine only could be demonstrated for any of the variables measured in our study setting. However, numerical advantages in terms of decreased length of stay as well as a lower clozapine dose at discharge were observed in the bitherapy group. Although this suggested numerical advantage for the EG in terms of the above variables could probably be attributed to the increased use of concomitant medication in this group, it would be important to note a comparison of the baseline data for the two groups. While not statistically significant, baseline data seemed to suggest that as a group the EG were more severely ill than the CG, as evidenced by (i) higher average length of stay at baseline, and (ii) a higher average clozapine dose on the most recent previous discharge. They also had more previous admissions, but this could just be in keeping with their longer duration of illness.
To date, no prospective control studies have been reported in the literature and the only studies that can possibly be used for comparison are that of Kho et al. 18 and James and Gray. clozapine. 27 Prescription of ECT-clozapine bitherapy therefore appears to be well tolerated and may be considered reasonably safe with few adverse effects. The main limitation of this study was the relatively small number of cases and the fact that study staff were not blinded to the treatment. Factors contributing to inability to consent to ECT could also have biased the sample choice. Strengths of the study include the use of a single setting (with established treatment guidelines)
as well as a single rater who conducted all assessments.
Conclusion
This pilot study represents the first controlled trial of ECT-clozapine bitherapy in a population with clozapine-refractory schizophrenia and schizoaffective disorder reported in the literature. In summary, despite the lack of statistically significant results in this study, lessons learnt from strengths and limitations could inform future study designs. The validity of our choice of current clinical practice at Stikland Hospital for the treatment of relapsed, noncompliant, known clozapine-refractory patients with a diagnosis of schizophrenia or schizoaffective disorder was not supported by our results. However, the study did provide us with preliminary evidence for the safety and efficacy of this combination. It would therefore be reasonable to continue to use this strategy in selected cases, at least until other clozapine-refractory treatment strategies become more available in our setting.
